Beyond CD34+ cell dose: impact of method of peripheral blood hematopoietic stem cell mobilization (granulocyte-colony-stimulating factor [G-CSF], G-CSF plus plerixafor, or cyclophosphamide G-CSF/granulocyte-macrophage [GM]-CSF) on number of colony-f
about
The CXCR4 and adhesion molecule expression of CD34+ hematopoietic cells mobilized by "on-demand" addition of plerixafor to granulocyte-colony-stimulating factor.Plerixafor is superior to conventional chemotherapy for first-line stem cell mobilisation, and is effective even in heavily pretreated patientsEndothelial progenitor cell: a blood cell by many other names may serve similar functionsPreclinical development and qualification of ZFN-mediated CCR5 disruption in human hematopoietic stem/progenitor cellsPlerixafor for mobilization of blood stem cells in autologous transplantation: an update.Engraftment and outcomes following autologous stem cell transplantation in Hodgkin lymphoma patients mobilized with plerixafor.Blood graft cellular composition and posttransplant recovery in non-Hodgkin's lymphoma patients mobilized with or without plerixafor: a prospective comparison.Engraftment and outcome after autologous stem cell transplantation in plerixafor-mobilized non-Hodgkin's lymphoma patients.Preemptive plerixafor injection added to pegfilgrastim after chemotherapy in non-Hodgkin lymphoma patients mobilizing poorly.Plerixafor is effective given either preemptively or as a rescue strategy in poor stem cell mobilizing patients with multiple myeloma.Growth factor plus preemptive ('just-in-time') plerixafor successfully mobilizes hematopoietic stem cells in multiple myeloma patients despite prior lenalidomide exposure.
P2860
Q34432943-742D7FA1-BEB7-43F4-B874-9831E84B1180Q34454624-61077BAD-E728-440E-A653-C249ECC4D277Q36991096-07DD2941-9470-4E85-A513-EF92F77BA314Q37403787-99E25953-9B8C-4762-AC36-911823D4CCEDQ38199707-23BE7423-A8F9-482F-87A6-6904637CE24AQ39958361-2E01CF48-780D-4524-B600-3EA53B23049AQ40896003-B18B8498-FC63-4690-9EE3-DCE99854273DQ43524297-CF05EF29-9679-43D5-BA9D-1B02775C1947Q47696715-CF03D177-6A04-4C74-8C04-ABE5E903F208Q51057684-4A79D1BC-8070-4696-83AB-AD836572E1C1Q51385709-C46D9B68-FDFF-4060-B146-530EBA957BFB
P2860
Beyond CD34+ cell dose: impact of method of peripheral blood hematopoietic stem cell mobilization (granulocyte-colony-stimulating factor [G-CSF], G-CSF plus plerixafor, or cyclophosphamide G-CSF/granulocyte-macrophage [GM]-CSF) on number of colony-f
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
Beyond CD34+ cell dose: impact ...... GM]-CSF) on number of colony-f
@en
Beyond CD34+ cell dose: impact ...... GM]-CSF) on number of colony-f
@nl
type
label
Beyond CD34+ cell dose: impact ...... GM]-CSF) on number of colony-f
@en
Beyond CD34+ cell dose: impact ...... GM]-CSF) on number of colony-f
@nl
prefLabel
Beyond CD34+ cell dose: impact ...... GM]-CSF) on number of colony-f
@en
Beyond CD34+ cell dose: impact ...... GM]-CSF) on number of colony-f
@nl
P2093
P2860
P1433
P1476
Beyond CD34+ cell dose: impact ...... GM]-CSF) on number of colony-f
@en
P2093
Ashley N Miller
Cindy Kramer
Erin T Alexander
Jeanne A Towery
Jerry E Squires
Kathy R Hogan
Luciano J Costa
P2860
P304
P356
10.1111/J.1537-2995.2011.03085.X
P577
2011-03-10T00:00:00Z